AU2001286468A1 - Micronized torsemide - Google Patents

Micronized torsemide

Info

Publication number
AU2001286468A1
AU2001286468A1 AU2001286468A AU8646801A AU2001286468A1 AU 2001286468 A1 AU2001286468 A1 AU 2001286468A1 AU 2001286468 A AU2001286468 A AU 2001286468A AU 8646801 A AU8646801 A AU 8646801A AU 2001286468 A1 AU2001286468 A1 AU 2001286468A1
Authority
AU
Australia
Prior art keywords
torsemide
micronized
present
microns
mean particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001286468A
Other languages
English (en)
Inventor
Judith Aronhime
Ben-Zion Dolitzky
David Leonov
Erzsebet Meszaros-Sos
Szabolcs Salyi
Anchel Schwartz
Shlomo Zavurov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of AU2001286468A1 publication Critical patent/AU2001286468A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Materials For Medical Uses (AREA)
AU2001286468A 2000-08-14 2001-08-14 Micronized torsemide Abandoned AU2001286468A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22536500P 2000-08-14 2000-08-14
US60225365 2000-08-14
PCT/US2001/025415 WO2002013823A1 (en) 2000-08-14 2001-08-14 Micronized torsemide

Publications (1)

Publication Number Publication Date
AU2001286468A1 true AU2001286468A1 (en) 2002-02-25

Family

ID=22844578

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001286468A Abandoned AU2001286468A1 (en) 2000-08-14 2001-08-14 Micronized torsemide

Country Status (11)

Country Link
US (1) US20020120147A1 (ja)
EP (1) EP1318809A1 (ja)
JP (1) JP2004511439A (ja)
KR (1) KR20030051618A (ja)
AU (1) AU2001286468A1 (ja)
CA (1) CA2419081A1 (ja)
IL (1) IL154457A0 (ja)
IS (1) IS6712A (ja)
NO (1) NO20030700L (ja)
PL (1) PL366219A1 (ja)
WO (1) WO2002013823A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200522943A (en) * 2003-12-11 2005-07-16 Kyowa Hakko Kogyo Kk Fine crystallites and a pharmaceutical composition comprising them
WO2006090350A1 (en) * 2005-02-28 2006-08-31 Ranbaxy Laboratories Limited A method for sieving pharmaceutical substances
EP2156837B1 (en) * 2007-05-21 2017-04-26 Toray Industries, Inc. Crystalline micropowder particles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
DE4323636A1 (de) * 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
KR20030051618A (ko) 2003-06-25
WO2002013823A1 (en) 2002-02-21
PL366219A1 (en) 2005-01-24
EP1318809A1 (en) 2003-06-18
IS6712A (is) 2003-02-11
CA2419081A1 (en) 2002-02-21
US20020120147A1 (en) 2002-08-29
IL154457A0 (en) 2003-09-17
JP2004511439A (ja) 2004-04-15
NO20030700D0 (no) 2003-02-13
NO20030700L (no) 2003-02-13

Similar Documents

Publication Publication Date Title
DE69831677T2 (de) Nanokristalline zubereitungen von menschlichen immunschwächevirus (hiv)-protease-in-hibitoren unter verwendung von zellulose-oberflächenstabilisatoren und verfahren zu deren herstellung
JP3696087B2 (ja) イトラコナゾール（ｉｔｒａｃｏｎａｚｏｌｅ）経口用製剤及びその製造方法
AU2014227473B2 (en) A Novel Formulation of Metaxalone
Maximiano et al. Benznidazole microcrystal preparation by solvent change precipitation and in vivo evaluation in the treatment of Chagas disease
BRPI0708343A2 (pt) formulações de carvedilol nanoparticuladas
UA111578C2 (uk) Спосіб одержання композиції, що містить напроксен
US7255877B2 (en) Fenofibrate microparticles
EP1283725B1 (en) Solid dispersion system of pranlukast with improved dissolution, and the preparing method thereof
Fontana et al. Spray-dried raloxifene submicron particles for pulmonary delivery: development and in vivo pharmacokinetic evaluation in rats
AU2001286468A1 (en) Micronized torsemide
JP2009515830A (ja) 微粉化アゾジカルボンアミド、その調製及びその使用
EP1465628A2 (en) Fine particle size pioglitazone
US20020077485A1 (en) Micronized leflunomide
US10603277B2 (en) Nanoparticulate formulation comprising a TRPA1 antagonist
US20190152930A1 (en) Formulation of metaxalone
JP2007099770A (ja) プランルカストを含有する噴霧−乾燥顆粒およびその製造方法
US20050238724A1 (en) Pharmaceutical composition containing lamotrigine particles of defined morphology
Merlos et al. Optimization and scaling-up of ITZ-based dry powders for inhalation
CN104411300A (zh) 抗逆转录病毒组合物
EP2540281A1 (en) Solid self-microemulsifying systems
US20020072602A1 (en) Micronized mirtazapine
Szaniawska Strategies in poorly soluble drug delivery systems
KR20170110285A (ko) 엘로티닙 나노입자 및 그 제조방법, 및 엘로티닙 나노입자를 함유하는 약학 조성물
WO2007064311A1 (en) Micronized mirtazapine
CN116159023A (zh) 一种生物利用度高的阿托伐醌混悬液及其制备方法